methionine has been researched along with imatinib mesylate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Limnander, A; Niki, M; Oki, S; Pandolfi, PP; Rothman, PB; Yao, PM | 1 |
| Lagonigro, MS; Miselli, F; Negri, T; Pilotti, S; Pricl, S; Tamborini, E | 1 |
| Albitar, M; Cortes, J; Giles, F; Kantarjian, H; Lee, TS; Potts, SJ | 1 |
| Bokelmann, K; Brockmöller, J; Koepsell, H; Mueller, T; Seitz, T; Tzvetkov, MV | 1 |
| Martins, JBL; Nascimento, ÉCM; Rocha, KML | 1 |
6 other study(ies) available for methionine and imatinib mesylate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation.
Topics: Animals; Apoptosis; Benzamides; Bone Marrow Cells; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Gene Expression Regulation, Leukemic; Imatinib Mesylate; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Methionine; Mice; Oncogene Proteins v-abl; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoproteins; Phosphoric Monoester Hydrolases; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; ras Proteins; RNA-Binding Proteins; Signal Transduction | 2005 |
Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
Topics: Alanine; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cysteine; Fibroma; Humans; Imatinib Mesylate; Leucine; Methionine; Mutagenesis; Mutation; Piperazines; Polymorphism, Genetic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Treatment Outcome | 2006 |
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Computer Simulation; Crystallography; Drug Resistance, Neoplasm; Genes, abl; Glutamic Acid; Humans; Imatinib Mesylate; Isoleucine; Methionine; Models, Molecular; Molecular Biology; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein-Tyrosine Kinases; Pyrimidines; Static Electricity; Threonine | 2008 |
Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?
Topics: Antineoplastic Agents; Benzamides; Codon, Nonsense; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gene Deletion; Genetic Carrier Screening; Haplotypes; HEK293 Cells; Humans; Imatinib Mesylate; Methionine; Organic Cation Transporter 1; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2014 |
Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein.
Topics: Afatinib; Antineoplastic Agents; Catalytic Domain; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methionine; Molecular Docking Simulation; Mutation; Quantum Theory; Sulfur | 2021 |